During the Phacilitate Leaders World and World Stem Cell Summit 2020 (FL, USA), Mike Brewer (Thermo Fisher Scientific; MA, USA) explains how mycoplasma can present serious challenges for the advancement and production of cellular therapies. He also talks through the MycoSEQ™ system, developed by Thermo Fisher Scientific, and how this can be used to quantify and overcome this problem.
About the author:
Mike Brewer is the Director, Regulatory and Global Principal Consultant for the BioProduction Division at Thermo Fisher Scientific. Here, he serves as the thought leader on regulation across all technology areas within the division, as well as being responsible for product applications across Microbiology, Analytical Sciences and Quality control.
Video originally published on RegMedNet, a digital platform from the Future Science Group that unites the diverse regenerative medicine community.